2026 Biomedical Pitch Competition
Day 2 Forum and Networking
70 个名额
现场参会请于 5/19 前完成报名
主题： Bridging the Gap: From Lab to Market in a Global Ecosystem
日期： 2026 年 5 月 24 日（星期日）
时间： 上午 9:00 – 下午 12:30（半日研讨会）
地点：
Fish & Richardson P.C 会议厅（17 楼）
1 Marina Park Drive, Boston, MA 02210
主办方：
Boston Capital Investment Club (BCIC)
Hong Kong Science and Technology Parks Corporation (HKSP)
活动概述
继 2026 Biomedical Pitch Competition 之后，本次研讨会汇聚国际专家，共同打通商业化的"最后一公里"，并促进战略合作与人脉对接。
议程
-
09:00 AM – 09:10 AM：开幕致辞
-
Jonathan Yi, President of BCIC
-
09:10 AM – 09:30 AM：Keynote I
-
演讲嘉宾： Weng-li Yoon, Associate Director, HKSTP
-
主题： Hong Kong as Asia's Emerging Biotech Hub.
-
09:30 AM – 09:40 AM：Keynote II — 场地赞助方致辞 Fish & Richardson P.C.
-
演讲嘉宾： Peng Lin, Partner, Fish & Richardson P.C.
-
09:40 AM – 11:00 AM：Panel Discussion — The Multi-Dimensional Launchpad
-
深入探讨 VC、CRO、Regulatory 与 Accelerator 多维视角。
-
嘉宾：
-
Weng-li Yoon, Associate Director, HKSTP
-
Peng Lin, Partner, Fish & Richardson P.C
-
Kate Zhang, Venture Partner at Tailwinds (NLVC)
-
Baolin (John) Wu, Executive Director of Technical Business Development
-
Han Zhang, Managing Director of BCIC
-
11:00 AM – 12:30 PM：Hybrid Networking & Close
报名信息
- 现场参会： 名额有限（70 位）
- 费用： $20
https://bcic.ticketspice.com/2026-biomedical-pitch-competition-forum-and-networking-part
Keynote 演讲嘉宾与 Panelist 简介
Wengli Yoon, Ph.D.
Associate Director (Therapeutics), Hong Kong Science and Technology Parks Corporation (HKSP)
Weng Li 是一位资深生物科技 R&D 领导者，在初创企业及跨国公司环境中拥有 20 余年国际经验，常驻英国与香港。
在 HKSTP 的现职中，Weng Li 与团队负责管理 HKSTP 内所有治疗领域企业的入驻与支持，涵盖 small molecules、biologics、cell and gene therapy、传统中医药及营养健康等模式。她同时领导 Clinical Translational Catalyst 项目，为 HKSTP 入驻企业的 IND-enabling 研究及临床试验提供资金支持。此外，她还在与香港大学和香港中文大学的联合管理委员会任职，负责筹建 cell and gene therapy 的 PIC/S GMP 中试生产设施。
Peng Lin, Ph.D.
Principal of Fish & Richardson P.C.
Peng 的客户涵盖大型上市生物制药公司及全球范围内的初创企业。他参与客户企业各成长阶段的工作，致力于深入理解客户技术，制定最优 IP 策略以最大化客户发明的商业价值。
Peng 以荣誉成绩毕业于 Harvard Law School。法学院前，他在 Washington University in St. Louis 取得人类遗传学与统计遗传学博士学位。Peng 在人类遗传、分子生物学、生物物理与生物信息学方向积累了深厚的研究与训练经验。他为客户提供广泛技术领域的专利咨询，包括 antibody therapeutics、transgenic animals、CAR-T 与 TCR-T 免疫疗法、microarray 技术、诊断方法、纳米颗粒技术、疫苗、small molecules、医疗器械、AI 在制药行业的应用等。
Peng 长期积极参与华人创业者社区。他自 2016 年起担任 Chinese Antibody Society 志愿者，并在 2024–2026 任期出任主席。Chinese Antibody Society 是一家致力于搭建抗体药物发现、开发、生产与商业化全球协作平台的非营利组织。
Peng 同时是 Kauffman Fellow（生物创业方向）。
Kate Zhang, Ph.D.
Venture Partner at Tailwinds (NLVC)
Dr. X. Kate Zhang 是一位战略型科学家与企业家，在生物制药行业拥有超过 30 年经验。她目前担任 Tailwinds (NLVC) 的 Venture Partner，凭借在药物开发方面的深厚背景，为新兴生物科技初创公司发掘投资机会并主导深入的科学尽调。Dr. Zhang 此前曾任 Hopewell Therapeutics 的 Chief Scientific Officer 及 Interim CEO，主导了 2,500 万美元种子轮融资，并为其 tissue-targeting lipid nanoparticle (ttLNP) 平台搭建起完整的 R&D 体系。她的职业经历还包括在 Editas Medicine 担任 VP of Biological Development，主导多项里程碑式 CRISPR-based IND 申报；并在 Sanofi 和 Genzyme 担任高级管理职位，参与了十款生物药的成功上市。Dr. Zhang 拥有超过 45 篇同行评议论文及多项专利，博士学位获自 Queen's University，并在 NIH 完成博士后训练。
Han Zhang (Moderator), Ph.D.
Managing Director, Boston Capital Investment Club (BCIC)
Han Zhang 博士现任 BCIC 总经理，负责在生命科学生态系统中连接 biotech 创始人、投资人与战略合作伙伴。他具备跨业务发展、竞争情报、生物医学信息学与转化科学的复合背景。早年他曾参与 Annoroad Gene Technology 创始团队，并陪伴公司走过 IPO 的成长历程。他亦曾任职于 Bristol Myers Squibb 与 SAS，积累了在生物制药、数据科学与分析领域的丰富经验。凭借生物医学信息学训练与对商业化策略的浓厚兴趣，Han 致力于在科学创新与市场洞察、合作策略及投资对话之间架起桥梁。
Baolin (John) Wu, Ph.D.
Executive Director of Technical Business Development
Dr. Baolin (John) Wu 是医药 CRDMO 行业的资深领导者，在 BD、客户管理、工艺开发与项目管理方面拥有 12 年以上经验。他擅长 small-molecule 开发与商业化生产，并在 ICH Q7 合规的 cGMP 运营方面有深厚积累。Dr. Wu 与全球生物制药及生物科技伙伴在复杂的开发与生产项目上紧密合作，并曾管理年收入超过 3,000 万美元的战略客户组合。在转任商业领导职位之前，Dr. Wu 参与了 40 余项临床与商业化生产项目以及 50 余项中美两地的开发与商业化项目。他的技术背景包括工艺放大、技术转移、连续流化学与酶催化转化。Dr. Wu 在 Wayne State University 获有机化学博士学位，并在工艺化学与相关领域合著了 17 篇科学论文。
Co-organizers and Sponsors
Name
Description
Boston Capital Investment Club (BCIC)
The Boston Capital Investment Club (BCIC) is a Massachusetts-registered non-profit organization serving nearly 10,000 professionals in finance, venture capital, and various technology industries. Beyond being a Boston-centered platform, the BCIC has grown to facilitate nationwide and international knowledge exchange across healthcare, finance, and related fields. Since 2022, the organization has hosted annual biomedical pitch competitions, empowering startups to secure over $300 million in collective funding.
Hong Kong Science and Technology Parks Corporation (HKSTP)
With a 20-year history of transforming lives through innovation, technology and entrepreneurship, Hong Kong Science and Technology Parks Corporation (HKSTP) has been propelling success for the most creative minds and innovators around the globe, accelerating ambitions and delivering positive impact from Hong Kong to the Greater Bay Area and the world. As an advocate for the innovative spirit, we strive to cultivate a diverse talent pool, connect research to innofacturing through "new industrialisation", and create a well-established I&T ecosystem that bridges innovators with high-potential partners and investors for ideas to grow and thrive.https://www.hkstp.org/
Fish & Richardson P.C.
As the leading IP law firm, we help innovators change the world through our unmatched litigation, prosecution, and post-grant experience across venues and prosecution needs. We touch more PTAB cases, IP appeals, and utility patents than anyone else, and no national firm handles more district court patent cases. Many of our 450+ attorneys and technology specialists are also scientists who are as comfortable in a lab or cleanroom as a courtroom or patent office. We're ready to hit the ground running to support your innovations, while distilling our vast technical and legal knowledge to resonate with business leaders or juries. You can be confident in every Fish lawyer in your corner because we intentionally build talent from the ground up and share knowledge generously and eagerly across the firm, leading to faster, fuller insights for you. Visionaries across eras have trusted us to protect their IP — from Alexander Graham Bell to today's largest phone makers — and we're ready to help build your IP strategy today with tomorrow in mind. Let's change the world together.
Shanghai InnoStar
Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar), was established in 2010. As a leading contract research organization, we adhere to the core values of "Science orientated, Quality first, Integrity & dedication, Win-win cooperation", and strive for innovative and reputational services with high quality and excellence. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification GLPmonitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).
Porton Pharma Solutions Ltd
Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products from pre-clinical to commercialization stages.
PanaCRO
PanaCRO is a full-service clinical CRO founded in 2004, helping global biotech and biopharma companies accelerate clinical development in China. With 500+ employees, coverage across 20+ provinces, collaboration with 800+ research sites, and experience supporting 200+ customers and 200+ clinical trials, PanaCRO provides end-to-end solutions from pre-IND/IND strategy and regulatory support to investigator-initiated trials (IITs), Phase I–III studies, NDA/BLA registration, and post-market real-world studies. With strong expertise in oncology, autoimmune diseases, infectious diseases, metabolic disorders, CNS, ophthalmology, and vaccines, PanaCRO combines deep local regulatory knowledge with international ICH-GCP standards to deliver efficient, high-quality clinical execution. As a trusted partner for innovative drug development, PanaCRO helps sponsors navigate China's clinical and regulatory landscape with speed, quality, and confidence
Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company with capabilities in R&D, production and professional marketing. It primarily focuses on the therapeutic areas of oncology, nervous system, autoimmune and antiinfection, with proactive forward-looking layout of disease areas that have significant clinical needs in the future, aiming to achieve the corporate mission of "providing today's patients with medicines of the future". Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many MNC, innovative companies, research institutes and clinical centers. In addition, Simcere has established several R&D innovation centers around the world. One of the innovation centers is Boston Innovation Center, located in Cambridge.
Fenwick
Fenwick is a top law firm serving technology and life sciences clients. With 500+ attorneys, we are nationally recognized for strengths in complex transactions, IP protection, M&A, "bet‑the‑company" litigation, and domestic and international tax. Since the 1980s, we've advised on international outsourcing, IP enforcement, foreign investment, and cross‑border tax matters. Our lawyers combine deep technical knowledge with a commitment to efficient, high‑quality service in a collaborative environment. Fenwick's landmark work includes incorporating Apple; pioneering the first shrink‑wrap license; negotiating an early software license with Bill Gates; taking Oracle, eBay, and 180+ others public; defending key biotech patents; and handling many of the industry's largest and most significant mergers and acquisitions.
